May 13, 2020 / 01:40PM GMT
Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity Research
Good day, everybody. My name is Jason Gerberry. I cover specialty pharma and biotech at Bank of America. I am pleased to be introducing our next company presenter, Alkermes, and CEO, Richard Pops. Alkermes is -- we all know Alkermes as a neuroscience-focused company although the company has some interesting developments in its pipeline in the oncology space. The company recently provided its first quarter update and some of the implications around the COVID-19 pandemic. So maybe Richard, I don't know -- to start, I don't know if you have any prepared remarks or if you want to provide any color just on sort of the 1Q update and how COVID-19 is impacting your business, and then we can jump into more specific questions from there.
Richard F. Pops - Alkermes plc - Chairman & CEO
Yes. I'll make a couple of remarks, Jason. First, I'll say good morning, and I hope you and the folks in your firm are well. It is a remarkable time. And we were just saying before we got on the call
Alkermes Plc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers